Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Jerome B. Zeldis net worth and biography

Jerome Zeldis Biography and Net Worth

Director of Soligenix

Jerome B. Zeldis has been a director since June 2011. Dr. Zeldis is currently Chief Medical Officer and President of Clinical Development of Sorrento Therapeutics, Inc. Previously, Dr. Zeldis was Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation. He was employed by Celgene from 1997 to 2016. From September 1994 to February 1997, Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He currently serves as Chairman of the board of Alliqua, Inc., and Trek Therapeutics, PBC, Vice Chairman of the board of MetaStat, Inc. and serves on the boards of Kalytera Therapeutics, Inc., BioSig Technologies, Inc., PTC Therapeutics, Inc., and AIT Therapeutics, Inc. Dr. Zeldis served as Assistant Professor of Medicine at the Harvard Medical School (from July 1987 to September 1988), Associate Professor of Medicine at University of California, Davis from (September 1988 to September 1994), Clinical Associate Professor of Medicine at Cornell Medical School (January 1995 to December 2003) and Professor of Clinical Medicine at the Robert Wood Johnson Medical School (July 1998 to June 2010). Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He has published 116 peer reviewed articles and 24 reviews, book chapters, and editorials.

What is Jerome B. Zeldis' net worth?: The estimated net worth of Jerome B. Zeldis is at least $37,685.64 as of May 26th, 2023. Mr. Zeldis owns 93,028 shares of Soligenix stock worth more than $37,686 as of April 19th. This net worth approximation does not reflect any other assets that Mr. Zeldis may own. Learn More about Jerome B. Zeldis' net worth.
How do I contact Jerome B. Zeldis?: The corporate mailing address for Mr. Zeldis and other Soligenix executives is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. Soligenix can also be reached via phone at (609) 538-8200 and via email at [email protected]. Learn More on Jerome B. Zeldis' contact information.
Has Jerome B. Zeldis been buying or selling shares of Soligenix?: Jerome B. Zeldis has not been actively trading shares of Soligenix in the last ninety days. Most recently, on Friday, May 14th, Jerome B. Zeldis bought 3,000 shares of Soligenix stock. The stock was acquired at an average cost of $0.89 per share, with a total value of $2,670.00. Following the completion of the transaction, the director now directly owns 25,917 shares of the company's stock, valued at $23,066.13. Learn More on Jerome B. Zeldis' trading history.
Who are Soligenix's active insiders?: Soligenix's insider roster includes Jonathan Guarino (CFO), Christopher Schaber (CEO), and Jerome Zeldis (Director). Learn More on Soligenix's active insiders.

Jerome B. Zeldis Insider Trading History at Soligenix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/14/2021	Buy	3,000	$0.89	$2,670.00	25,917
11/19/2019	Buy	2,000	$0.96	$1,920.00
9/19/2019	Buy	4,000	$0.94	$3,760.00	20,917
4/22/2019	Buy	10,000	$0.73	$7,300.00	16,917
12/23/2015	Buy	2,500	$1.27	$3,175.00	69,166

Jerome B. Zeldis Buying and Selling Activity at Soligenix

Soligenix Company Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase IIa clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $0.43

$0.39

$0.44

50 Day Range

MA: $0.63

$0.39

$0.82

2 Week Range

Now: $0.43

$0.37

$4.20

Volume

1,011,750 shs

Average Volume

3,091,656 shs

Market Capitalization

$4.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81